Top

Molecular Pain

Published in:

Open Access 01-12-2010 | Research

Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia

Authors: Guang Bai, Dong Wei, Shiping Zou, Ke Ren, Ronald Dubner

Published in: Molecular Pain | Issue 1/2010

Abstract

Background

Several classes of histone deacetylases (HDACs) are expressed in the spinal cord that is a critical structure of the nociceptive pathway. HDAC-regulated histone acetylation is an important component of chromatin remodeling leading to epigenetic regulation of gene transcription. To understand the role of histone acetylation in epigenetic regulation of pathological pain, we have studied the impact of different classes of HDACs in the spinal cord on inflammatory hyperalgesia induced by complete Freund's adjuvant (CFA).

Results

We intrathecally applied inhibitors specific to different classes of HDACs and evaluated their impact on inflammatory hyperalgesia. Pre-injected inhibitors targeting class I as well as II (SAHA, TSA, LAQ824) or IIa (VPA, 4-PB) HDACs significantly delayed the thermal hyperalgesia induced by unilateral CFA injection in the hindpaw. Existing hyperalgesia induced by CFA was also attenuated by the HDAC inhibitors (HDACIs). In contrast, these inhibitors did not interfere with the thermal response either in naïve animals, or on the contralateral side of inflamed animals. Interestingly, MS-275 that specifically inhibits class I HDACs failed to alter the hyperalgesia although it increased histone 3 acetylation in the spinal cord as SAHA did. Using immunoblot analysis, we further found that the levels of class IIa HDAC members (HDAC4, 5, 7, 9) in the spinal dorsal horn were upregulated following CFA injection while those of class I HDAC members (HDAC1, 2, 3) remained stable or were slightly reduced.

Conclusions

Our data suggest that activity of class II HDACs in the spinal cord is critical to the induction and maintenance of inflammatory hyperalgesia induced by CFA, while activity of class I HDACs may be unnecessary. Comparison of the effects of HDACIs specific to class II and IIa as well as the expression pattern of different HDACs in the spinal cord in response to CFA suggests that the members of class IIa HDACs may be potential targets for attenuating persistent inflammatory pain.

Available only for authorised users

LaCroix-Fralish ML, Ledoux JB, Mogil JS: The Pain Genes Database : An interactive web browser of pain-related transgenic knockout studies. Pain 2007, 131: 3.e1–3.e4. 10.1016/j.pain.2007.04.041CrossRef

Geranton SM, Morenilla-Palao C, Hunt SP: A role for transcriptional repressor methyl-CpG-binding protein 2 and plasticity-related gene serum- and glucocorticoid-inducible kinase 1 in the induction of inflammatory pain states. J Neurosci 2007, 27: 6163–6173. 10.1523/JNEUROSCI.1306-07.2007CrossRef

Griffin RS, Costigan M, Brenner GJ, Ma CH, Scholz J, Moss A, Allchorne AJ, Stahl GL, Woolf CJ: Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci 2007, 27: 8699–8708. 10.1523/JNEUROSCI.2018-07.2007CrossRef

Rohl T, Kurreck J: RNA interference in pain research. J Neurochem 2006, 99: 371–380. 10.1111/j.1471-4159.2006.04082.xCrossRef

Cheng HY, Pitcher GM, Laviolette SR, Whishaw IQ, Tong KI, Kockeritz LK, Wada T, Joza NA, Crackower M, Goncalves J, Sarosi I, Woodgett JR, Oliveira-dos-Santos AJ, Ikura M, van der Kooy D, Salter MW, Penninger JM: DREAM is a critical transcriptional repressor for pain modulation. Cell 2002, 108: 31–43. 10.1016/S0092-8674(01)00629-8CrossRef

Duric V, McCarson KE: Neurokinin-1 (NK-1) receptor and brain-derived neurotrophic factor (BDNF) gene expression is differentially modulated in the rat spinal dorsal horn and hippocampus during inflammatory pain. Mol Pain 2007, 3: 32. 10.1186/1744-8069-3-32PubMedCentralCrossRef

Tegeder I, Niederberger E, Schmidt R, Kunz S, Guhring H, Ritzeler O, Michaelis M, Geisslinger G: Specific Inhibition of I{kappa}B Kinase Reduces Hyperalgesia in Inflammatory and Neuropathic Pain Models in Rats. J Neurosci 2004, 24: 1637–1645. 10.1523/JNEUROSCI.3118-03.2004CrossRef

Diatchenko L, Nackley AG, Tchivileva IE, Shabalina SA, Maixner W: Genetic architecture of human pain perception. Trends Genet 2007, 23: 605–613. 10.1016/j.tig.2007.09.004CrossRef

Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447: 433–440. 10.1038/nature05919CrossRef

10.

Jiang Y, Langley B, Lubin FD, Renthal W, Wood MA, Yasui DH, Kumar A, Nestler EJ, Akbarian S, Beckel-Mitchener AC: Epigenetics in the Nervous System. J Neurosci 2008, 28: 11753–11759. 10.1523/JNEUROSCI.3797-08.2008PubMedCentralCrossRef

11.

Henderson I, Jacobsen S: Epigenetic inheritance in plants. Nature 2007, 447: 418–424. 10.1038/nature05917CrossRef

12.

Mattick JS: Challenging the dogma: the hidden layer of non-protein-coding RNAs in complex organisms. Bioessays 2003, 25: 930–939. 10.1002/bies.10332CrossRef

13.

Kouzarides T: Chromatin modifications and their function. Cell 2007, 128: 693–705. 10.1016/j.cell.2007.02.005CrossRef

14.

Haberland M, Montgomery RL, Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10: 32–42. 10.1038/nrg2485PubMedCentralCrossRef

15.

Fukuda H, Sano N, Muto S, Horikoshi M: Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct Genomic Proteomic 2006, 5: 190–208. 10.1093/bfgp/ell032CrossRef

16.

Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Sobue G: Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004, 13: 1183–1192. 10.1093/hmg/ddh131CrossRef

17.

Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413: 739–743. 10.1038/35099568CrossRef

18.

McCampbell A, Taye AA, Whitty L, Penney E, Steffan JS, Fischbeck KH: Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci USA 2001, 98: 15179–15184. 10.1073/pnas.261400698PubMedCentralCrossRef

19.

Thomas EA: Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Mol Neurobiol 2009, 40: 33–45. 10.1007/s12035-009-8067-yCrossRef

20.

Butler R, Bates GP: Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 2006, 7: 784–796. 10.1038/nrn1989CrossRef

21.

Monneret C: Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drugs 2007, 18: 363–370. 10.1097/CAD.0b013e328012a5dbCrossRef

22.

Renthal W, Maze I, Krishnan V, Covington HE, Xiao G, Kumar A, Russo SJ, Graham A, Tsankova N, Kippin TE, Kerstetter KA, Neve RL, Haggarty SJ, McKinsey TA, Bassel-Duby R, Olson EN, Nestler EJ: Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007, 56: 517–529. 10.1016/j.neuron.2007.09.032CrossRef

23.

Lucio-Eterovic AK, Cortez MA, Valera ET, Motta FJ, Queiroz RG, Machado HR, Carlotti CG, Neder L, Scrideli CA, Tone LG: Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008, 8: 243. 10.1186/1471-2407-8-243PubMedCentralCrossRef

24.

Broide RS, Redwine JM, Aftahi N, Young W, Bloom FE, Winrow CJ: Distribution of histone deacetylases 1–11 in the rat brain. J Mol Neurosci 2007, 31: 47–58. 10.1007/BF02686117CrossRef

25.

Cunliffe VT: Histone deacetylase 1 is required to repress Notch target gene expression during zebrafish neurogenesis and to maintain the production of motoneurones in response to hedgehog signalling. Development 2004, 131: 2983–2995. 10.1242/dev.01166CrossRef

26.

Fischer DD, Cai R, Bhatia U, Asselbergs FAM, Song C, Terry R, Trogani N, Widmer R, Atadja P, Cohen D: Isolation and Characterization of a Novel Class II Histone Deacetylase, HDAC10. J Biol Chem 2002, 277: 6656–6666. 10.1074/jbc.M108055200CrossRef

27.

Chiechio S, Zammataro M, Morales ME, Busceti CL, Drago F, Gereau RW, Copani A, Nicoletti F: Epigenetic Modulation of mGlu2 Receptors by Histone Deacetylase Inhibitors in the Treatment of Inflammatory Pain. Mol Pharmacol 2009, 75: 1014–1020. 10.1124/mol.108.054346CrossRef

28.

Sternberg WF, Ridgway CG: Effects of gestational stress and neonatal handling on pain, analgesia, and stress behavior of adult mice. Physiol Behav 2003, 78: 375–383. 10.1016/S0031-9384(03)00015-5CrossRef

29.

Coutinho SV, Plotsky PM, Sablad M, Miller JC, Zhou H, Bayati AI, McRoberts JA, Mayer EA: Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol 2002, 282: G307–316.CrossRef

30.

Bernardi M, Genedani S, Tagliavini S, Bertolini A: Effects on long-term sensitivity to pain and morphine of stress induced in the newborn rat by pain or manipulation. Physiol Behav 1986, 37: 827–831. 10.1016/0031-9384(86)90191-5CrossRef

31.

Ren K, Anseloni V, Zou SP, Wade EB, Novikova SI, Ennis M, Traub RJ, Gold MS, Dubner R, Lidow MS: Characterization of basal and re-inflammation-associated long-term alteration in pain responsivity following short-lasting neonatal local inflammatory insult. Pain 2004, 110: 588–596. 10.1016/j.pain.2004.04.006CrossRef

32.

Rodier PM: Environmental Causes of Central Nervous System Maldevelopment. Pediatrics 2004, 113: 1076–1083.

33.

Fejer R, Hartvigsen J, Kyvik KO: Heritability of neck pain: a population-based study of 33 794 Danish twins. Rheumatology 2006, 45: 589–594. 10.1093/rheumatology/kei224CrossRef

34.

Bellos F, Mahlknecht U: Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 2008, 31: 629–633. 10.1159/000160599CrossRef

35.

Kuendgen A, Gattermann N: Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110: 943–954. 10.1002/cncr.22891CrossRef

36.

Bialer M, Yagen B: Valproic Acid: second generation. Neurotherapeutics 2007, 4: 130–137. 10.1016/j.nurt.2006.11.007CrossRef

37.

Vinik A: CLINICAL REVIEW: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005, 90: 4936–4945. 10.1210/jc.2004-2376CrossRef

38.

Lussier D, Huskey AG, Portenoy RK: Adjuvant analgesics in cancer pain management. Oncologist 2004, 9: 571–591. 10.1634/theoncologist.9-5-571CrossRef

39.

Adcock IM, Tsaprouni L, Bhavsar P, Ito K: Epigenetic regulation of airway inflammation. Curr Opin Immunol 2007, 19: 694–700. 10.1016/j.coi.2007.07.016CrossRef

40.

Butler KV, Kozikowski AP: Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 2008, 14: 505–528. 10.2174/138161208784480180CrossRef

41.

Glauben R, Sonnenberg E, Zeitz M, Siegmund B: HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett 2009, 280: 154–159. 10.1016/j.canlet.2008.11.019CrossRef

42.

Kuendgen A, Gattermann N: Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110: 943–954. 10.1002/cncr.22891CrossRef

43.

Johannessen CU, Johannessen SI: Valproate: past, present, and future. CNS Drug Rev 2003, 9: 199–216. 10.1111/j.1527-3458.2003.tb00249.xCrossRef

44.

Rajan I, Savelieva KV, Ye G-L, Wang C-y, Malbari MM, Friddle C, Lanthorn TH, Zhang W: Loss of the Putative Catalytic Domain of HDAC4 Leads to Reduced Thermal Nociception and Seizures while Allowing Normal Bone Development. PLoS ONE 2009, 4: e6612. 10.1371/journal.pone.0006612PubMedCentralCrossRef

45.

Uchida H, Ma L, Ueda H: Epigenetic gene silencing underlies C-fiber dysfunctions in neuropathic pain. J Neurosci 2010, 30: 4806–4814. 10.1523/JNEUROSCI.5541-09.2010CrossRef

46.

Dokmanovic M, Clarke C, Marks PA: Histone Deacetylase Inhibitors: Overview and Perspectives. Mol Cancer Res 2007, 5: 981–989. 10.1158/1541-7786.MCR-07-0324CrossRef

47.

Banner LR, Patterson PH, Allchorne A, Poole S, Woolf CJ: Leukemia Inhibitory Factor Is an Anti-Inflammatory and Analgesic Cytokine. J Neurosci 1998, 18: 5456–5462.

48.

Winkler I, Blotnik S, Shimshoni J, Yagen B, Devor M, Bialer M: Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br J Pharmacol 2005, 146: 198–208. 10.1038/sj.bjp.0706310PubMedCentralCrossRef

49.

Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20: 6969–6978. 10.1093/emboj/20.24.6969PubMedCentralCrossRef

50.

Balasubramanian S, Verner E, Buggy JJ: Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009, 280: 211–221. 10.1016/j.canlet.2009.02.013CrossRef

51.

Ellis L, Atadja PW, Johnstone RW: Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009, 8: 1409–1420. 10.1158/1535-7163.MCT-08-0860CrossRef

52.

Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C: Histone deacetylase inhibitors and genomic instability. Cancer Lett 2009, 274: 169–176. 10.1016/j.canlet.2008.06.005CrossRef

53.

Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008, 409: 581–589. 10.1042/BJ20070779CrossRef

54.

Bhalla KN: Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies. J Clin Oncol 2005, 23: 3971–3993. 10.1200/JCO.2005.16.600CrossRef

55.

Eikel D, Hoffmann K, Zoll K, Lampen A, Nau H: S -2-pentyl-4-pentynoic hydroxamic acid and its metablite s -2-pentyl-4--pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides. Drug Metab Dispos 2006, 34: 612–620. 10.1124/dmd.105.008078CrossRef

56.

Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, Costa E, Guidotti A: The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006, 103: 1587–1592. 10.1073/pnas.0510341103PubMedCentralCrossRef

57.

Hahnen E, Ilker Y, Eyüpoglu IY, Brichta L, Haastert K, Tränkle C, Siebzehnrübl FA, Riessland M, Hölker I, Claus P, Romstöck J, Buslei R, Wirth B, Blümcke I: In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 2006, 98: 193–202. 10.1111/j.1471-4159.2006.03868.xCrossRef

58.

Tjølsen A, Berge O-G, Hunskaar S, Rosland JH, Hole K: The formalin test: an evaluation of the method. Pain 1992, 51: 5–17. 10.1016/0304-3959(92)90003-TCrossRef

59.

Coderre T, Melzack R: The role of NMDA receptor-operated calcium channels in persistent nociception after formalin-induced tissue injury. J Neurosci 1992, 12: 3671–3675.

60.

Ren K, Dubner R: Enhanced descending modulation of nociception in rats with persistent hindpaw inflammation. J Neurophysiol 1996, 76: 3025–3037.

61.

Covington HEI, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O, Fass DM, Renthal W, Rush AJI, Wu EY, Ghose S, Krishnan V, Russo SJ, Tamminga C, Haggarty SJ, Nestler EJ: Antidepressant Actions of Histone Deacetylase Inhibitors. J Neurosci 2009, 29: 11451–11460. 10.1523/JNEUROSCI.1758-09.2009PubMedCentralCrossRef

62.

Hwang CK, Kim CS, Kim DK, Law P-Y, Wei L-N, Loh HH: Up-regulation of the mu opioid receptor gene is mediated through chromatin remodeling and transcriptional factors in differentiated neuronal cells. Mol Pharmacol 2010. published on-line by April 12, 2010

63.

Bi J, Hu X, Loh HH, Wei L-N: Regulation of Mouse {kappa} Opioid Receptor Gene Expression by Retinoids. J Neurosci 2001, 21: 1590–1599.

64.

Wang G, Liu T, Wei L-N, Law P-Y, Loh HH: DNA Methylation-Related Chromatin Modification in the Regulation of Mouse {delta}-Opioid Receptor Gene. Mol Pharmacol 2005, 67: 2032–2039. 10.1124/mol.105.011056CrossRef

65.

Kieffer BL, Gavériaux-Ruff C: Exploring the opioid system by gene knockout. Prog Neurobiol 2002, 66: 285–306. 10.1016/S0301-0082(02)00008-4CrossRef

66.

Biggs J, Lu V, Stebbing M, Balasubramanyan S, Smith P: Is BDNF sufficient for information transfer between microglia and dorsal horn neurons during the onset of central sensitization? Mol Pain 2010, 6: 44. 10.1186/1744-8069-6-44PubMedCentralCrossRef

67.

Wei F, Dubner R, Zou S, Ren K, Bai G, Wei D, Guo W: Molecular Depletion of Descending Serotonin Unmasks Its Novel Facilitatory Role in the Development of Persistent Pain. J Neurosci 2010, 30: 8624–8636. 10.1523/JNEUROSCI.5389-09.2010PubMedCentralCrossRef

68.

Huang Y, Doherty JJ, Dingledine R: Altered Histone Acetylation at Glutamate Receptor 2 and Brain-Derived Neurotrophic Factor Genes Is an Early Event Triggered by Status Epilepticus. J Neurosci 2002, 22: 8422–8428.

69.

Bredy TW, Wu H, Crego C, Zellhoefer J, Sun YE, Barad M: Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem 2007, 14: 268–276. 10.1101/lm.500907PubMedCentralCrossRef

70.

Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ: Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9: 519–525. 10.1038/nn1659CrossRef

71.

Mariadason JM: HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008, 3: 28–37. 10.4161/epi.3.1.5736CrossRef

72.

Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, Yao J, Zhou L, Zeng Y, Li H, Li Y, Shi J, An W, Hancock SM, He F, Qin L, Chin J, Yang P, Chen X, Lei Q, Xiong Y, Guan K-L: Regulation of Cellular Metabolism by Protein Lysine Acetylation. Science 2010, 327: 1000–1004. 10.1126/science.1179689PubMedCentralCrossRef

73.

Wang Q, Zhang Y, Yang C, Xiong H, Lin Y, Yao J, Li H, Xie L, Zhao W, Yao Y, Ning Z-B, Zeng R, Xiong Y, Guan K-L, Zhao S, Zhao G-P: Acetylation of Metabolic Enzymes Coordinates Carbon Source Utilization and Metabolic Flux. Science 2010, 327: 1004–1007. 10.1126/science.1179687PubMedCentralCrossRef

74.

Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions. Science 2009, 325: 834–840. 10.1126/science.1175371CrossRef

75.

Niederberger E, Geisslinger G: The IKK-NF-{kappa}B pathway: a source for novel molecular drug targets in pain therapy? FASEB J 2008, 22: 3432–3442. 10.1096/fj.08-109355CrossRef

76.

Lee KM, Kang BS, Lee HL, Son SJ, Hwang SH, Kim DS, Park JS, Cho HJ: Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur J Neurosci 2004, 19: 3375–81. 10.1111/j.0953-816X.2004.03441.xCrossRef

77.

McKinsey TA, Zhang CL, Olson EN: Identification of a Signal-Responsive Nuclear Export Sequence in Class II Histone Deacetylases. Mol Cell Biol 2001, 21: 6312–6321. 10.1128/MCB.21.18.6312-6321.2001PubMedCentralCrossRef

78.

Lachner M, O'Sullivan RJ, Jenuwein T: An epigenetic road map for histone lysine methylation. J Cell Sci 2003, 116: 2117–2124. 10.1242/jcs.00493CrossRef

79.

Yang X-J, Gregoire S: Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication. Mol Cell Biol 2005, 25: 2873–2884. 10.1128/MCB.25.8.2873-2884.2005PubMedCentralCrossRef

80.

Robinson DA, Wei F, Wang GD, Li P, Kim SJ, Vogt SK, Muglia LJ, Zhuo M: Oxytocin mediates stress-induced analgesia in adult mice. J Physiol 2002, 540: 593–606. 10.1113/jphysiol.2001.013492PubMedCentralCrossRef

81.

Iadarola MJ, Brady LS, Draisci G, Dubner R: Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. Pain 1988, 35: 313–326. 10.1016/0304-3959(88)90141-8CrossRef

82.

Bai G, Zhuang ZY, Liu AG, Chai YF, Hoffman PW: The role of the RE1 element in activation of the NR1 promoter during neuronal differentiation. J Neurochem 2003, 86: 992–1005. 10.1046/j.1471-4159.2003.01922.xCrossRef

83.

Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji S, Bai G, Zhang X: Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005, 115: 3104–3116. 10.1172/JCI25509PubMedCentralCrossRef

Title: Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia
Authors: Guang Bai
Dong Wei
Shiping Zou
Ke Ren
Ronald Dubner
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Molecular Pain / Issue 1/2010
Electronic ISSN: 1744-8069
DOI: https://doi.org/10.1186/1744-8069-6-51

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia

Abstract

Background

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Aromatase and 5-alpha reductase gene expression: modulation by pain and morphine treatment in male rats

Changes in Aβ non-nociceptive primary sensory neurons in a rat model of osteoarthritis pain

Expression genetics identifies spinal mechanisms supporting formalin late phase behaviors

Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain

Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats

KATP channel subunits in rat dorsal root ganglia: alterations by painful axotomy